U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22ClN5O2
Molecular Weight 423.8961
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOLIBRESIB

SMILES

CCN=C(C[C@@]1([H])c2nnc(C)n2-c3ccc(cc3C(=N1)c4ccc(cc4)Cl)OC)O

InChI

InChIKey=AAAQFGUYHFJNHI-SFHVURJKSA-N
InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1

HIDE SMILES / InChI
Molecular Formula C22H22ClN5O2
Molecular Weight 423.8961
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21068722 | https://www.ncbi.nlm.nih.gov/pubmed/24015967

GSK 525768A is inactive enantiomer of BET inhibitor, compound I-BET (GSK525762A). It was used as a negative controls in studies of I-BET.

Originator

Approval Year

Unknown
116683
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
7701
 42.4 nM [IC50]
Inhibitor
7701
 32.5 nM [IC50]
Inhibitor
7701
 36.1 nM [IC50]
Inhibitor
7701
Inhibitor
7701
Inhibitor
7701
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
Unknown

Approved Use

Unknown
Primary
Phase II
Unknown

Approved Use

Unknown
Primary
Phase II
Unknown

Approved Use

Unknown
Primary
Phase II
Unknown

Approved Use

Unknown
Primary
Phase II
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
918.6 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32328561
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GSK-525762 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1080.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32328561
100 mg 1 times / day single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GSK-525762 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3818.5 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32328561
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GSK-525762 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7294.6 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32328561
100 mg 1 times / day single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GSK-525762 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.82 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32328561
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GSK-525762 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32328561
100 mg 1 times / day single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GSK-525762 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors.
2012 Sep 4
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
2014 Jan 30
CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.
2016 Feb
Patents

Patents

EP-3050885-A1
2
US-9102677-B2
2
WO2015049629A1
2
WO2016014859A1
2
WO2016196065A1
2

Sample Use Guides

In Vivo Use Guide
GSK 525762, at the 60-100 mg QD doses, resulted in partial responses in two patients at 15 and 23 weeks, respectively, and stable disease in four patients, according to data from 11 treated patients with NUT midline carcinoma, in a phase I/II study
Route of Administration: Oral
In Vitro Use Guide
125-500 nM I-BET-762 (GSK 525762) treatment differentially alters CD4+ T-cell cytokine production
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:41:54 UTC 2021
Edited
by admin
on Sat Jun 26 16:41:54 UTC 2021
Record UNII
5QIO6SRZ2R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOLIBRESIB
INN  
USAN   INN  
Official Name English
GSK525762
Code English
I-BET 762
Code English
GSK525762A
Code English
MOLIBRESIB [INN]
Common Name English
GSK-525762A
Code English
GSK-525762
Code English
MOLIBRESIB [USAN]
Common Name English
MOLIBRESIB [WHO-DD]
Common Name English
4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE-4-ACETAMIDE, 6-(4-CHLOROPHENYL)-N-ETHYL-8-METHOXY-1-METHYL-, (4S)-
Systematic Name English
BET INHIBITOR GSK525762
Common Name English
2-((4S)-6-(4-CHLOROPHENYL)-8-METHOXY-1-METHYL-4HBENZO(F)(1,2,4)TRIAZOLO(4,3-A)(1,4)DIAZEPIN-4-YL)-N-ETHYLACETAMIDE
Systematic Name English
(4S)-6-(4-CHLOROPHENYL)-N-ETHYL-8-METHOXY-1-METHYL-4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE-4-ACETAMIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C128462
Created by admin on Sat Jun 26 16:41:54 UTC 2021 , Edited by admin on Sat Jun 26 16:41:54 UTC 2021
Code System Code Type Description
EPA CompTox
1260907-17-2
Created by admin on Sat Jun 26 16:41:54 UTC 2021 , Edited by admin on Sat Jun 26 16:41:54 UTC 2021
PRIMARY
PUBCHEM
46943432
Created by admin on Sat Jun 26 16:41:54 UTC 2021 , Edited by admin on Sat Jun 26 16:41:54 UTC 2021
PRIMARY
INN
10533
Created by admin on Sat Jun 26 16:41:54 UTC 2021 , Edited by admin on Sat Jun 26 16:41:54 UTC 2021
PRIMARY
FDA UNII
5QIO6SRZ2R
Created by admin on Sat Jun 26 16:41:54 UTC 2021 , Edited by admin on Sat Jun 26 16:41:54 UTC 2021
PRIMARY
NCI_THESAURUS
C101538
Created by admin on Sat Jun 26 16:41:54 UTC 2021 , Edited by admin on Sat Jun 26 16:41:54 UTC 2021
PRIMARY
CAS
1260907-17-2
Created by admin on Sat Jun 26 16:41:54 UTC 2021 , Edited by admin on Sat Jun 26 16:41:54 UTC 2021
PRIMARY
Related Record Type Details
Structure of MOLIBRESIB BESYLATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of MOLIBRESIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966